Elo Mutual Pension Insurance Co Has $11.27 Million Holdings in Stryker Co. (NYSE:SYK)

Elo Mutual Pension Insurance Co lowered its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 3.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,298 shares of the medical technology company's stock after selling 1,287 shares during the quarter. Elo Mutual Pension Insurance Co's holdings in Stryker were worth $11,269,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Swedbank AB lifted its position in Stryker by 10.9% during the third quarter. Swedbank AB now owns 51,070 shares of the medical technology company's stock worth $18,450,000 after purchasing an additional 5,032 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Stryker during the 3rd quarter worth approximately $317,000. Avestar Capital LLC lifted its holdings in shares of Stryker by 1.1% during the 3rd quarter. Avestar Capital LLC now owns 2,948 shares of the medical technology company's stock worth $1,065,000 after acquiring an additional 31 shares during the period. Townsquare Capital LLC increased its stake in Stryker by 11.9% in the third quarter. Townsquare Capital LLC now owns 7,468 shares of the medical technology company's stock valued at $2,698,000 after acquiring an additional 792 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund raised its position in Stryker by 162.3% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 144,283 shares of the medical technology company's stock valued at $52,124,000 after purchasing an additional 89,283 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Remove Ads

Stryker Trading Down 0.9 %

Shares of Stryker stock traded down $3.16 during midday trading on Friday, reaching $364.38. The company had a trading volume of 1,274,307 shares, compared to its average volume of 1,289,456. The firm has a market cap of $139.08 billion, a PE ratio of 46.96, a P/E/G ratio of 2.93 and a beta of 0.95. The stock has a fifty day moving average price of $384.08 and a 200 day moving average price of $374.32. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the company posted $3.46 EPS. On average, equities analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.92%. Stryker's payout ratio is currently 43.30%.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of research analyst reports. JPMorgan Chase & Co. raised their target price on Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Wells Fargo & Company lifted their target price on Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a research report on Wednesday, January 29th. Barclays increased their target price on shares of Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Needham & Company LLC reaffirmed a "buy" rating and set a $442.00 price target on shares of Stryker in a report on Friday, March 21st. Finally, Argus set a $450.00 price objective on shares of Stryker in a research note on Monday, February 3rd. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $421.90.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company's stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.